JAMA Oncology

04/16/2026

A retrospective cohort study described medical assistance in dying (MAID) among adolescent and young adult patients with in Alberta, Canada. Among 34 individuals aged 15 to 39 years at cancer diagnosis who received MAID before age 45, symptom burden increased steadily particularly for tiredness, pain, and poor well-being in the year prior to MAID, with sharp rises beginning around five months before provision.

Specialist palliative care was most often initiated less than three months before death, and qualitative themes included social isolation, loss of meaningful activities, and a desire for control. These data indicate that symptom escalation and advanced cancer diagnosis may serve as prompts for timelier palliative care referrals in this population.

https://ja.ma/481ItAy

04/14/2026

The 9-valent vaccine was linked to reduced risk of in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. https://ja.ma/4t4Ur4E

04/11/2026

Genomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability.

This genomic profiling study describes the molecular architecture of 1104 prospective consecutive meningioma samples from one academic medical center.

04/10/2026

Among patients with advanced who received pembrolizumab for 22 to 26 months and survived at least 29 months, overall survival rates remained high up to 48 months after stopping immunotherapy.

Subsequent treatments were mostly chemotherapy and radiotherapy, while immunotherapy rechallenge was uncommon. These findings demonstrate that most long-term survivors maintained favorable outcomes post-discontinuation, with limited use of immunotherapy after initial treatment completion.

https://ja.ma/3QuIOWc

04/09/2026

In a large multicenter retrospective cohort study, males aged 9 to 26 years who received at least one dose of the 9-valent human papillomavirus ( ) vaccine demonstrated a lower risk of composite —including head and neck, esophageal, a**l, and pe**le cancers—compared with unvaccinated males.

The association persisted across both adolescent (9-14 years) and young adult (15-26 years) groups, supporting the benefit of sex-neutral HPV vaccination strategies for reducing cancer burden in males.

https://ja.ma/47PDiU4

04/09/2026

In the BRIGHT-2 phase 3 randomized clinical trial, bireociclib plus fulvestrant significantly prolonged median progression-free survival for patients with hormone receptor–positive, ERBB2-negative advanced after prior endocrine therapy progression, compared to placebo plus fulvestrant. Improvements in objective response rate and disease control rate were observed for bireociclib-treated patients.

Safety outcomes were consistent with other cyclin-dependent kinase 4/6 inhibitors, including manageable rates of diarrhea and neutropenia. These findings support bireociclib plus fulvestrant as a treatment option for advanced breast cancer after endocrine progression.

https://ja.ma/4rKeVhJ

04/04/2026

Clonal hematopoiesis of indeterminate potential (CHIP) was associated with increased risk of trastuzumab-related cardiotoxic effects among patients with in both a large UK Biobank cohort and an independent cohort from Seoul National University Hospital.

CHIP positivity was associated with higher incidence of heart failure and cardiotoxic events by multiple clinical definitions.

https://ja.ma/4sT4TfA

04/03/2026

Pretreatment magnetic resonance imaging (MRI) parameters including extraprostatic extension and seminal vesicle invasion were independently associated with higher risk of biochemical recurrence, metastatic failure, and prostate cancer-specific mortality among men undergoing radical prostatectomy.

Quantitative MRI features such as Prostate Imaging Reporting and Data System score, tumor diameter, and apparent diffusion coefficient also provided prognostic value for recurrence, even after adjusting for clinicopathologic factors. These findings confirm that prostate MRI adds independent prognostic information for long-term outcomes in men treated with radical prostatectomy.



https://ja.ma/41JRLNL

04/03/2026

The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. https://ja.ma/4s5ajCT

04/02/2026

Low-dose aspirin in older adults was not associated with lower incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period. https://ja.ma/4dYHggV

04/01/2026

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. https://ja.ma/4tkLDr8